Quantum BioPharma Ltd. is trading 3.2% down today at $5.08, extending a steep multi-day slide following last week’s double-digit declines.
- The U.S. FDA has placed a clinical hold on the company’s IND application for Lucid-MS, its lead candidate for multiple sclerosis.
- Management was forced to withdraw previously communicated Phase 2 timelines while it prepares responses to the FDA's information requests.
- The stock continues to face significant downward pressure as investors react to the regulatory setback and the resulting uncertainty surrounding the clinical program.